Latest stories on CLRB
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
The Fly47 · neutralearnings
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha67 · bullishproduct/pr
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Cellectar Biosciences, Inc. (CLRB) files 8-K
SEC 8-K50 · neutralgeneral
Cellectar Biosciences GAAP EPS of -$0.57 misses by $0.05
Seeking Alpha34 · bearishearnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire56 · neutralearnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Insider56 · neutralearnings
Cellectar Biosciences Q2 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Business Insider50 · neutralgeneral
Cellectar Biosciences, Inc. (CLRB) files 8-K
SEC 8-K50 · neutralgeneral
Cellectar Biosciences Bets on Iopofosine Breakthrough
TipRanks56 · neutralproduct/pr
Cellectar Biosciences Announces Board Changes and New Director
TipRanks50 · neutralgeneral
Cellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027
Seeking Alpha67 · bullishproduct/pr
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings